SCHEMBL17899879

SCHEMBL17899879

CCOC(=O)C(C)(C)Sc1ccc2cnsc2c1-c1ccncc1

nearest known ligand 0.58

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 12/20 0.58
LATS1 O95835 1/20 0.40
CDC7 O00311 4/20 0.37
DBF4 Q9UBU7 4/20 0.37
ALDH1A1 P00352 2/20 0.36
NPSR1 Q6W5P4 1/20 0.35
MEN1 O00255 1/20 0.35
POLB P06746 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17899840 0.86 SLC22A12 (0.68) SLC22A12
SCHEMBL19449100 0.86 SLC22A12 (0.55) SLC22A12ALDH1A1NPSR1MEN1POLB
SCHEMBL17899849 0.85 SLC22A12 (0.75) SLC22A12ALDH1A1
SCHEMBL19562887 0.85 SLC22A12 (0.54) SLC22A12ALDH1A1NPSR1MEN1POLB
SCHEMBL17899909 0.85 SLC22A12 (0.78) SLC22A12
SCHEMBL17899852 0.83 SLC22A12 (0.52) SLC22A12ALDH1A1NPSR1MEN1POLB
SCHEMBL23129640 0.79 SLC22A12 (0.56) SLC22A12
SCHEMBL19435490 0.79 SLC22A12 (0.62) SLC22A12ALDH1A1
SCHEMBL23129667 0.77 SLC22A12 (0.54) SLC22A12
SCHEMBL19435472 0.76 SLC22A12 (0.77) SLC22A12ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3241822-B1 URAT1 INHIBITOR NIPPON CHEMIPHAR CO (JP) 2021-03-24 EP claimed
CN-107108478-B URAT1 inhibitors 日本化学药品株式会社 2020-04-24 CN claimed
US-10173990-B2 URAT1 inhibitor NIPPON CHEMIPHAR CO., LTD. (JP) 2019-01-08 US claimed
EP-3241822-A1 URAT1 INHIBITOR Nippon Chemiphar Co., Ltd. (JP) 2017-11-08 EP claimed
US-20170290795-A1 URAT1 INHIBITOR J-PHARMA CO., LTD. (JP) 2017-10-12 US claimed
EP-3241822-B1 URAT1 INHIBITOR NIPPON CHEMIPHAR CO (JP) 2021-03-24 EP disclosed
CN-107108478-B URAT1 inhibitors 日本化学药品株式会社 2020-04-24 CN disclosed
US-10173990-B2 URAT1 inhibitor NIPPON CHEMIPHAR CO., LTD. (JP) 2019-01-08 US disclosed
US-10173990-B2 URAT1 inhibitor NIPPON CHEMIPHAR CO., LTD. (JP) 2019-01-08 US disclosed
EP-3241822-A1 URAT1 INHIBITOR Nippon Chemiphar Co., Ltd. (JP) 2017-11-08 EP disclosed
US-20170290795-A1 URAT1 INHIBITOR J-PHARMA CO., LTD. (JP) 2017-10-12 US disclosed
US-20170290795-A1 URAT1 INHIBITOR J-PHARMA CO., LTD. (JP) 2017-10-12 US disclosed
US-20170290795-A1 URAT1 INHIBITOR J-PHARMA CO., LTD. (JP) 2017-10-12 US disclosed
WO-2016108282-A1 URAT1 INHIBITOR 日本ケミファ株式会社 2016-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170290795-A1 URAT1 INHIBITOR SLC10A1, XDH, URB2 SLC22A12 512/4885LATS1 2299/4885CDC7 3269/4885
US-10173990-B2 URAT1 inhibitor SLC10A1, XDH, URB2 SLC22A12 500/4885LATS1 2284/4885CDC7 3309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.